Cited by 335Drug-Induced Hepatotoxicity and ProtectionImmunotoxicology and immune responsesLiver physiology and pathology

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species

Abstract

Hepatotoxic doses of acetaminophen to mice produce not only acetaminophen-protein adducts in the centrilobular cells of the liver, but nitrotyrosine-protein adducts in the same cells, the site of the necrosis. Nitration of tyrosine occurs with peroxynitrite, a species formed by reaction of nitric oxide (NO · ) with superoxide (O 2 ·− ). Because NO · and O 2 ·− may be produced by activated Kupffer cells and/or infiltrated macrophages, we pretreated mice with the macrophage inactivators/depeleters gadolinium chloride (7 mg/kg, intravenously [iv]) or dextran sulfate (10 mg/kg, iv) 24 hours before administration of acetaminophen (300 mg/kg). Mice treated with acetaminophen plus gadolinium chloride, or acetaminophen plus dextran sulfate, had significantly less evidence of hepatotoxicity as evidenced by lower serum alanine transaminase (ALT) levels (28 ± 1 IU/L and 770 ± 240 IU/L, respectively) at 8 hours compared with acetaminophen (6,380 ± 408 IU/L). Analysis of hepatic homogenates for acetaminophen-protein adducts at 2 hours, a time of maximal covalent binding and before hepatocyte lysis, indicated that these pretreatments did not decrease covalent binding. Western blot analysis for the macrophage marker protein F4/80 in homogenates revealed not only the expected decrease by the macrophage inactivators/depleters, but also an apparent increase in acetaminophen-only-treated mice. At 8 hours nitrotyrosine-protein adducts were present in the acetaminophen-only-treated mice, but not in the acetaminophen plus gadolinium chloride-treated mice, or acetaminophen plus dextran sulfate-treated mice. High levels of heme-protein adducts, a measure of oxidative stress, were detected in livers of the 8 hour acetaminophen-only-treated mice. These data suggest that acetaminophen hepatotoxicity is mediated by an initial metabolic activation and covalent binding, and subsequent activation of macrophages to form O 2 ·− , NO · , and peroxynitrite. Nitration of tyrosine correlates with toxicity.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.510300104

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The cytochrome P450 (CYP450) system, especially CYP2E1, has been known to enhance the toxic damage caused by paracetamol by increasing the formation of NAPQI.

    “On the other hand, cytochrome P450 (CYP450) system, especially CYP2E1 has been known to enhance the toxic damage caused by paracetamol by increasing the formation of NAPQI. 5”
  • Paracetamol toxicity is mainly due to reduction of hepatocyte GSH and increased CYP2E1 activity.

    “The mechanism behind paracetamol toxicity is mainly due to the reduction of hepatocyte GSH and increased CYP2E1 activity where paracetamol is metabolized to an extremely reactive toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) along with generation of reactive oxygen species in augmenting oxidative stress. 3,5,6”
  • Paracetamol is metabolized to the reactive toxic metabolite NAPQI, with generation of reactive oxygen species that augment oxidative stress.

    “The mechanism behind paracetamol toxicity is mainly due to the reduction of hepatocyte GSH and increased CYP2E1 activity where paracetamol is metabolized to an extremely reactive toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) along with generation of reactive oxygen species in augmenting oxidative stress. 3,5,6”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. Hinson, 1980, Rev Biochem Toxicol, 2, 103
  2. Dahlin, 1984, Proc Natl Acad Sci U S A, 81, 1327, 10.1073/pnas.81.5.1327 · DOI · Paper page
  3. Mitchell, 1973, J Pharmacol Exp Ther, 187, 211
  4. Jollow, 1973, J Pharmacol Exp Ther, 187, 195
  5. Hinson, 1995, Drug Metab Rev, 27, 73, 10.3109/03602539509029816 · DOI
  6. Roberts, 1991, Am J Pathol, 138, 359
  7. Cohen, 1997, Drug Metab Rev, 29, 59, 10.3109/03602539709037573 · DOI
  8. Bartolone, 1987, Biochem Pharmacol, 36, 1193, 10.1016/0006-2952(87)90069-4 · DOI
  9. Cohen, 1997, Toxicol Appl Pharmacol, 143, 1, 10.1006/taap.1996.8074 · DOI
  10. Laskin, 1995, Ann Rev Pharmacol Toxicol, 35, 655, 10.1146/annurev.pa.35.040195.003255 · DOI
  11. Winwood, 1993, Semin Liver Dis, 13, 733, 10.1055/s-2007-1007337 · DOI
  12. Blazka, 1996, J Inflamm, 47, 138
  13. Goldin, 1996, J Pathol, 179, 432, 10.1002/(SICI)1096-9896(199608)179:4<432::AID-PATH609>3.0.CO;2-S · DOI
  14. Laskin, 1995, Hepatology, 21, 1045, 10.1002/hep.1840210424 · DOI
  15. Nakae, 1990, Am J Pathol, 136, 787
  16. Hinson, 1998, Chem Res Toxicol, 11, 604, 10.1021/tx9800349 · DOI · Paper page
  17. Beckman, 1996, Am J Physiol, 271, c1424, 10.1152/ajpcell.1996.271.5.C1424 · DOI · Paper page
  18. Pryor, 1995, Am J Physiol, 268, l699
  19. Beckman, 1994, Biol Chem Hoppe-Seyler, 375, 81, 10.1515/bchm3.1994.375.2.81 · DOI
  20. Gardner, 1998, Hepatology, 27, 748, 10.1002/hep.510270316 · DOI
  21. Matthews, 1996, Drug Metab Dispos, 24, 1192
  22. Vuletich, 1998, Toxicologist, 42, 219s
  23. Pumford, 1989, J Pharmacol Exp Ther, 248, 182
  24. Hirsch, 1982, Immunobiology, 161, 298, 10.1016/S0171-2985(82)80086-7 · DOI
  25. Hume, 1984, Anat Rec, 210, 503, 10.1002/ar.1092100311 · DOI
  26. McKnight, 1996, J Biol Chem, 271, 486, 10.1074/jbc.271.1.486 · DOI
  27. MacMicking, 1997, Annu Rev Immunol, 15, 323, 10.1146/annurev.immunol.15.1.323 · DOI
  28. Roland, 1996, J Leukoc Biol, 60, 487, 10.1002/jlb.60.4.487 · DOI
  29. Hardonk, 1992, J Leukoc Biol, 52, 296, 10.1002/jlb.52.3.296 · DOI
  30. Walker, 1981, Toxicol Appl Pharmacol, 59, 500, 10.1016/0041-008X(81)90303-3 · DOI
  31. Lee, 1985, J Exp Med, 161, 475, 10.1084/jem.161.3.475 · DOI
  32. Hagen, 1994, Proc Natl Acad Sci U S A, 91, 12808, 10.1073/pnas.91.26.12808 · DOI
  33. Boess, 1998, Hepatology, 27, 1021, 10.1002/hep.510270418 · DOI
  34. Scott, 1984, Invest Ophthalmol Vis Sci, 25, 599
  35. Sies, 1997, J Biol Chem, 272, 27812, 10.1074/jbc.272.44.27812 · DOI
  36. Padmaja, 1998, Arch Biochem Biophys, 349, 1, 10.1006/abbi.1997.0407 · DOI
  37. DeLeve, 1997, Biochem Pharmacol, 53, 1339, 10.1016/S0006-2952(97)00048-8 · DOI
  38. Kuo, 1994, J Surg Res, 56, 594, 10.1006/jsre.1994.1094 · DOI
  39. Alexander, 1998, Nutrition, 14, 376, 10.1016/S0899-9007(97)00492-9 · DOI
  40. Dai, 1995, J Pharmacol Exp Ther, 273, 1497

Cited by

Sorted by citations

Metadata

Authors
Michael, S. L., Pumford, N. R., Mayeux, P. R., Niesman, M. R., & Hinson, J. A.
Affiliations
University of Arkansas for Medical Sciences (US)
Corresponding author
Hinson, Jack A.
Venue
Hepatology
Published
1999-07
Volume
30
Issue
1
Pages
186-195
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2033635345
Cited by
335
References
1
Citations by year
2026: 5 · 2025: 7 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 11 · 2017: 18 · 2016: 9 · 2015: 14 · 2014: 17 · 2013: 13 · 2012: 21
FWCI
7.87
Type
journal article
Language
en
Open access
closed
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of General Medical Sciences (R01GM058884, R01GM048749)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK44716)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
acetaminophen hepatotoxicity, gadolinium chloride, dextran sulfate, Kupffer cells, macrophages, peroxynitrite, nitric oxide, superoxide, reactive oxygen species, reactive nitrogen species, oxidative stress, F4/80, alanine aminotransferase, liver necrosis
MeSH terms
Acetaminophen, Alanine Transaminase, Animals, Anti-Inflammatory Agents, Aspartate Aminotransferases, Gadolinium, Kupffer Cells, Liver, Macrophage Activation, Macrophages, Male, Mice, Inbred Strains, Necrosis, Nitrates, Nitric Oxide, Superoxides, Dextran Sulfate, Oxidants, Reactive Oxygen Species, Oxidative Stress, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review